Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study

BACKGROUND: Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). AIMS: To evaluate the association between age and comorbidity with safety and effectiveness outcomes of vedolizumab and ustekinumab in IB...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Aliment Pharmacol Ther
Hlavní autoři: Asscher, Vera E. R., Biemans, Vince B. C., Pierik, Marieke J., Dijkstra, Gerard, Löwenberg, Mark, van der Marel, Sander, de Boer, Nanne K. H., Bodelier, Alexander G. L., Jansen, Jeroen M., West, Rachel L., Haans, Jeoffrey J. L., van Dop, Willemijn A., Weersma, Rinse K., Hoentjen, Frank, Maljaars, P. W. Jeroen
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Efficacy and Safety of Biologics for Crohn's Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539998/
https://ncbi.nlm.nih.gov/pubmed/32901983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.16073
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky